

DIVI'S LABORATORIES LIMITED
Hyderabad

PRESS RELEASE dated 20th May, 2011


Divi's Labs PAT for Q4 grew by 36% to Rs.175 crores

Divi's Laboratories has earned a PAT of Rs.175 crores on an income of Rs. 481 crores for the 4th quarter of the year 2010-11 on a consolidated basis. PAT for the corresponding previous quarter was Rs. 129 crores on an income of Rs. 315 crores. For the quarter, while the income grew by 53% over the corresponding quarter of last year, the PAT has grown by 36%.

For the current year, the company earned a consolidated PAT of Rs.429 crores on a total income of Rs. 1318 crores as against a PAT of Rs. 340 crores last year on an income of Rs. 964 crores. On year-on-year basis, the total income grew by 37% over the last year and the PAT has grown by 26%.

The Board of Directors of the company has recommended a dividend of Rs.10 per equity share of Rs.2 each (i.e., 500%) for the year.


Business has grown satisfactorily across all segments, especially during the second half of the year. The issue of destocking of inventory at our customers seen during the last

year is done with and we see normal flow of business across the product portfolio of the company. As has been the trend, exports constituted 93% of sales and about 75% to advanced markets in North America and Europe.

The company has commissioned a part of the DSN SEZ facility at Visakhapatnam and commenced trial runs from the Unit during May, 2011.

The company has a total of 41 drug master files (DMFs) with US-FDA and Certificate of Suitability with European Directorate for 12 products. It also has dossiers for 28 products with other countries. The company filed 18 patents in India and 12 patents in the USA for generic products.



A handwritten signature in black ink is positioned to the left of a circular stamp. The stamp contains the text "BIJI'S LABORATORIES LTD." around the top edge, "Hyderabad-16" in the center, and "DK Road Ametpet" around the bottom edge, flanked by two small stars.